Benztropine mesylate is a centrally acting muscarinic acetylcholine receptor antagonist and dopamine transporter (DAT) inhibitor (IC50 = 118 nM). Benztropine mesylate has been used to treat the symptoms of Parkinson′s disease and is currently in clincial trials for chronic back pain.
Benztropine mesylate serves as an inhibitor of breast cancer stem cells (BCSCs) in vitro and
in vivo. It can help in improving the efficacy of chemotherapy
in vitro. It is considered as an anti-cancer stem cell (CSC) drug, which can modify tumorigenic properties.
[1]